 Posters highlight Palatins ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J. , May 2, 2022 PRNewswire -- Palatin Technologies, Inc. Palatin NYSE American: PTN, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two poster presentations at the Association for Research in Vision and Ophthalmology ARVO Annual Conference being held May 1-4 in Denver. 